When the plasma physics community gathers for its biggest annual event, the Princeton Plasma Physics Laboratory (PPPL) shows up in force. This year's ...

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

NORMAN, Okla. (AP) Mohamed Wague scored a career-high 20 points and grabbed seven rebounds, Nijel Pack added 18 points, and Oklahoma Sooners took down in-state foe Oral Roberts Golden Eagles 95-71 on ...

PRINCETON, N.J., Nov. 13, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced the presentation ...

AI and ML are increasingly influential in separation science, with growing interest in their application for method development and laboratory automation. Oligonucleotides and RNA therapeutics remain ...

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

Join us to support research presentations for the Diversity Summer Internship Program. 26 interns with projects across departments in the School of Public Health will be showcasing their summer ...

This site is available to all users in English. EBU Members can log in to access our website in 20 additional languages as well. This innovation is powered by the EBU’s internal AI engine, EuroVox.

Please provide your email address to receive an email when new articles are posted on . Mid- to late-career medical oncologists from NCI-designated cancer centers delivered a high percentage of oral ...

“Over the last year, our progress on two preclinical gene therapy programs as well as our novel AAV capsid discovery platform has been remarkable,” said P. Peter Ghoroghchian, MD, PhD, CEO of Latus.

Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...